At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 255 enrolled
Drug / intervention
JNJ-77242113 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating JNJ-77242113 and Placebo for Plaque Psoriasis. Completed, enrolled 255 participants across 76 sites in 10 countries.
Detailed Summary
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, France, Germany, Japan, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartFeb 2022
First PostedFeb 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedFeb 4, 2022
Enrollment StartFeb 3, 2022
Primary CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.4 years ago
Interventions
JNJ-77242113drug
JNJ-77242113 tablet will be administered orally.
Placebodrug
Placebo tablet will be administered orally.